Document is current

Article History

Accepted: 27 November 2024

First Online: 3 January 2025

Declarations

:

: No funding was received for the preparation of this article.

: L.W. has received honoraria from the pharmaceutical companies of UCB and Veriton Pharma to provide talks to peer audiences. M.K. has received honoraria to provide talks to peer audiences and for conference travel from UCB, Eisai and Angelini Pharma. R.S. is the chief investigator of the NIHR adopted national Ep-ID register (which is described in the paper and evidence from it used). The Register is supported and monitored by the National Institute of Health Research UK. The funding for each molecule examined by the Register is via an Investigator Initiated Support grant from each of the molecule’s parent company. The funding is to RSs’ NHS institution and goes towards the salary of the research co-ordinator and the institution’s project oversight costs. The contributing companies to date include Eisai, UCB, Bial and Jazz Pharmaceuticals (previously GW pharma). In addition to the above, R.S. has received institutional research, travel support and/or honorarium for talks and expert advisory boards from LivaNova, UCB, Eisai, Veriton Pharma, Bial, Angelini, UnEEG and Jazz/GW Pharma outside the submitted work. He holds or has held competitive grants from various national grant bodies including Innovate, Economic and Social Research Council (ESRC), Engineering and Physical Sciences Research Council (ESPRC), National Institute of Health Research (NIHR), NHS Small Business Research Initiative (SBRI) and other funding bodies including charities, all outside this work.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: L.W.: initial draft of manuscript and outline, initial literature search and review, and revision of work based upon feedback comments from author team and reviewer. M.K.: literature review and draft of Novel Drugs and Non-Pharmacological interventions. R.S.: corresponding author, development of idea and core outline, review of draft editions and revision, and final overview of manuscript prior to submission. All authors have read and approve the final submitted manuscript, and agree to be accountable for the work.